Skip to main content
Equibles
HBIO logo

HBIO · Harvard Bioscience Inc

Track HBIO — free

Use HBIO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about HBIO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.66 -0.02 (-0.22%) At close · Aug 14
Market Cap
$30.30M
Shares
4.55M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.66 Open$6.61 Day$6.51–6.70 Since split$4.31–7.24 Avg vol 30d15K Short int61K · 1.3% float · 5.3d Short vol57% Last earningsAug 11, 2026 DataMar 2026–Aug 2026 Filing10-Q · Aug 11

Raw chart and full-history price indicators begin at the captured split on Mar 16, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Mar 16, 2026.

Up next

Next earnings call
Nov 8, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Buy Momentum Limited Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 50-day avg +8%
      above
      RSI (14) 61
      neutral
      MACD trend Positive
      52-week position 80%
      mid-range
      Momentum
      relative strength
      Limited
      Not enough data for a confident read.
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50/200-day averages unavailable
      Institutional flow Flat
      0% holders QoQ · +4 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      1.35% of float · ▲ +9.6% MoM · 5.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      37 holders — near 3-yr low, contrarian setup
      Squeeze score 64
      elevated · 0–100
      Fundamentals
      Weak
      Revenue growth −4%
      Y/Y
      Gross margin 43%
      contracting
      EPS growth −357%
      Y/Y
      Free cash flow $5.5M
      Balance sheet $27.3M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 82%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 4.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 11, 2026
      third quarter 2026
      Revenue Initiated $21M – $22.6M
      prior qtr $22.73M midpoint −4.1% QoQ
      Adjusted gross margin Non-GAAP Initiated 56% – 58%
      Adjusted EBITDA Non-GAAP Initiated $1.5M – $2.5M
      full year 2026
      Adjusted gross margin Non-GAAP Initiated 57% – 59%
      Adjusted EBITDA growth Non-GAAP Initiated 6% – 10%
      Prior guidance period ended · from the 8-K filed May 12, 2026
      Revenue · Q2 2026 $20.5M – $22.5M
      Adjusted gross margin · Q2 2026 57% – 59%
      Adjusted EBITDA · Q2 2026 $1M – $2M
      Guided vs delivered · last 1 settled
      Revenues fourth quarter 2025
      guided $22.5M – $24.5M
      $23.74M In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      61 Neutral
      MACD trend
      Positive Bullish
      52-week position
      80% Neutral
      Market signals — smart money & positioning
      Bearish · 1 of 6
      Trend (MA cross) No cross
      50/200-day averages unavailable
      Institutional flow Flat
      0% holders QoQ · +4 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      1.35% of float · ▲ +9.6% MoM · 5.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      37 holders — near 3-yr low, contrarian setup
      Price context
      position in its range since split · 2026-03-16
      Range low $4 Now $7 · 80% Range high $7
      vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted gross margin non-GAAP 58.3% Six Months Ended June 30, 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Instruments & Supplies — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      HBIO
      Harvard Bioscience Inc
      this stock
      		$30.30M — -3.8% — 1.3%
      ISRG
      Intuitive Surgical Inc
      		 $139.37B -30.3% +20.5% 45.3 1.9%
      BDX
      Becton Dickinson & Co
      		 $49.96B — +8.2% — 3.7%
      MDLN
      Medline Inc.
      		 $46.99B -14.9% +11.5% — 2.6%
      ALC
      Alcon Inc
      		 $35.89B -5.8% +10.5% — 2.8%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      37
      % held
      36.9%
      Net QoQ
      +93.8K sh
      Top holder
      WEBER CAPITAL MANAGEMENT…
      Held Float
      View
      Held by Funds
      Fund positions
      19
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      61.4K
      Days to cover
      5.3d
      Change
      +5.4K sh
      View
      Short Volume
      Short vol %
      57%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      98
      Value
      $593
      As of
      Jul 2, 2026
      View
      Off-Exchange
      Off-exchange %
      54.4%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $86.6M
      Net income (FY)
      $-56.7M
      EPS diluted
      $-12.80
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 11, 2026
      This year
      18
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 11, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Mar 16, 2026; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      HBIO +2.9% +6.8% — +9.1% —
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +2.5% +2.4% — +5.2% —
      Key facts CIK 1123494 CUSIP 416906204 13F (30d) 42 filings 35 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)